^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FGFR (Fibroblast Growth Factor Receptor)

    i
    Other names: FGFR, Fibroblast Growth Factor Receptor
    3d
    Proteome-Wide Analysis of Functional Phosphosites in the FGFR Family of Proteins: Insights from Large-Scale Phosphoproteomic Analysis. (PubMed, Proteomes)
    Our findings highlight key disease-associated phosphosites within the FGFRs and offer a foundation for advancing phosphosite-focused therapeutic research.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • MAPK1 (Mitogen-activated protein kinase 1)
    4d
    Expanding the therapeutic applications of PARP inhibitors in cancer by targeting receptor tyrosine kinases. (PubMed, Biochim Biophys Acta Rev Cancer)
    Key molecular mechanisms underlying these synergistic effects include modulation of reactive oxygen species production, PARP activation, HR pathway regulation, cell cycle control, and induction of autophagy and apoptosis. Nevertheless, challenges including drug resistance, toxicity, and heterogeneous clinical responses highlight the need for biomarker-driven patient selection, optimized dosing schedules, and a deeper understanding of tumor-specific signaling crosstalk.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • FGFR (Fibroblast Growth Factor Receptor) • AXL (AXL Receptor Tyrosine Kinase)
    |
    BRCA2 mutation • BRCA1 mutation
    5d
    Engineering a Gd₂(WO₄)₃-P@rGO heterostructure for enhanced electrochemical sensing and therapeutic drug monitoring of erdafitinib. (PubMed, Mikrochim Acta)
    Recovery studies in spiked human serum and urine samples yielded excellent results (95.7-104.8% recovery, RSD ≤ 3.65%), validating the sensor's real-world applicability. Importantly, the sensor offers scalable fabrication, requires no toxic reducing agents, and exhibits strong selectivity and long-term stability, making it a novel and sustainable platform for therapeutic drug monitoring, pharmacokinetics, and point-of-care diagnostics.
    Journal
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    Balversa (erdafitinib)
    6d
    FT400-004: Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL (clinicaltrials.gov)
    P1, N=10, Completed, Zhejiang University | Recruiting --> Completed | N=16 --> 10 | Trial completion date: Aug 2025 --> May 2025 | Trial primary completion date: Aug 2025 --> May 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • JAK2 (Janus kinase 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • IKZF1 (IKAROS Family Zinc Finger 1) • JAK1 (Janus Kinase 1) • IL7R (Interleukin 7 Receptor) • TCF3 (Transcription Factor 3) • SH2B3 (SH2B Adaptor Protein 3)
    |
    SH2B3 mutation
    6d
    CR109248: A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (clinicaltrials.gov)
    P1, N=5, Active, not recruiting, Janssen Pharmaceutical K.K. | Trial completion date: Sep 2027 --> Aug 2026 | Trial primary completion date: Oct 2026 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR mutation • FGFR fusion
    |
    erdafitinib intravesical delivery system (TAR-210)
    10d
    MoonRISe-1: A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (clinicaltrials.gov)
    P3, N=641, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2028 --> Dec 2032
    Trial completion date
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR mutation • FGFR fusion
    |
    gemcitabine • erdafitinib intravesical delivery system (TAR-210)
    11d
    FGFR Testing in Metastatic Urothelial Carcinoma-Who, When, and How to Test. (PubMed, Cancers (Basel))
    This has broadened the treatment landscape of the disease to include novel agents, such as antibody-drug conjugates (e.g., enfortumab vedotin) and targeted therapies, including the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib. Equally important is the standardization and timely implementation of FGFR3 testing in clinical practice to optimize treatment planning. This review addresses key considerations in FGFR3 testing in mUC and discusses how it can be routinely incorporated into clinical practice.
    Review • Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor)
    |
    Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
    11d
    Paediatric Therapeutic Development Workshop on rhabdoid tumours. (PubMed, Br J Cancer)
    Mouse double minute 2 homologue (MDM2) is a priority target for novel therapeutic development and combination trials. Combinations of EZH2, MDM2 inhibitors and selective inhibitors of nuclear export should be evaluated robustly preclinically and drive early clinical studies.
    Review • Journal
    |
    FGFR (Fibroblast Growth Factor Receptor) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • DDB1 (Damage Specific DNA Binding Protein 1)
    11d
    FGFR-Driven Lung Cancer: Dissecting Resistance and Exploring Therapeutic Avenues. (PubMed, Crit Rev Oncol Hematol)
    Innovative approaches, including the second-generation FGFR TKIs, monoclonal antibodies (mAbs), FGF traps, antibody-drug conjugates, and synergistic combinations with immunotherapy or other receptor tyrosine kinase (RTK) inhibitors, are discussed to overcome resistance. Overall, this review offers theoretical insights and proposes strategies to tackle resistance to FGFR-directed treatments in lung cancer.
    Review • Journal • IO biomarker
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR mutation
    13d
    Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas (clinicaltrials.gov)
    P1, N=40, Recruiting, M.D. Anderson Cancer Center | N=20 --> 40
    Enrollment change
    |
    FGFR (Fibroblast Growth Factor Receptor) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    |
    ulixertinib (BVD-523)
    13d
    Pembrolizumab, Olaparib, and Temozolomide for People With Glioma (clinicaltrials.gov)
    P2, N=57, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FGFR (Fibroblast Growth Factor Receptor) • CDK12 (Cyclin dependent kinase 12) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CHEK2 (Checkpoint kinase 2) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
    |
    CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
    17d
    Predictive and Prognostic Value of p16 in Head and Neck Squamous Cell Carcinoma Patients Treated with Molecular Targeted Agents or Immune Checkpoint Inhibitors: Subgroup Analysis of the TRIUMPH Study. (PubMed, Cancer Invest)
    Patients with p16 (+) showed longer PFS and OS compared to p16 (-) patients. This suggests that p16 has prognostic and predictive values in HNSCC patients who are treated with MTAs or ICIs.
    Journal • Checkpoint inhibition • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR (Fibroblast Growth Factor Receptor)